LLY - ELI LILLY & Co
813.48
11.830 1.454%
Share volume: 3,072,760
Last Updated: 03-14-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.19%
PREVIOUS CLOSE
CHG
CHG%
$801.65
11.83
0.01%
Fundamental analysis
81%
Profitability
100%
Dept financing
33%
Liquidity
57%
Performance
80%
Performance
5 Days
-1.96%
1 Month
-5.10%
3 Months
4.43%
6 Months
-11.92%
1 Year
7.86%
2 Year
146.91%
Key data
Stock price
$813.48
DAY RANGE
$800.00 - $815.21
52 WEEK RANGE
$711.40 - $972.53
52 WEEK CHANGE
$6.66
DIVIDEND
$1.50
EX-DIVIDEND DATE
02-14-2025
NEXT EARNINGS DATE
N/A
Company detail

CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news